Valuation: Kalaris Therapeutics, Inc.

Market Cap 50.7M 45.42M 41.9M 37.92M 70.9M 4.83B 72.05M 500M 199M 2.53B 190M 186M 8B P/E 2026 *
-1.07x
P/E 2027 * -1.37x
Enterprise Value -4.64M -4.15M -3.83M -3.47M -6.48M -442M -6.59M -45.71M -18.24M -231M -17.4M -17.03M -732M EV / Sales 2026 *
-
EV / Sales 2027 * -6.68x
Free-Float
91.19%
Yield 2026 *
-
Yield 2027 * -
1 day+3.33%
1 week-6.53%
Current month-35.64%
1 month-35.86%
3 months-45.29%
6 months-66.24%
Current year-77.96%
1 week 1.78
Extreme 1.78
2.16
1 month 1.78
Extreme 1.78
2.93
Current year 1.78
Extreme 1.78
11.22
1 year 1.78
Extreme 1.78
11.88
3 years 1.78
Extreme 1.78
12.9
5 years 1.78
Extreme 1.78
12.9
10 years 1.78
Extreme 1.78
12.9
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26 Free

Controller/Auditor

10,000 0.0420%
8/1/26 Free

Director

18,000 0.0757%
7/27/26 Other

Controller/Auditor

48,363 0.2033%
Change 5-day change 1-year change 3-year change Capi.($)
+3.33%-6.53%-61.81% - 47.85M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
+0.18%-1.44%+23.40%-10.61% 24.23B
Average +0.32%+3.07%+41.04%+162.70% 39.26B
Weighted average by Cap. +0.10%+3.59%+49.30%+160.58%

Financials

2026 *2027 *
Net sales - 11.43M 10.24M 9.44M 8.55M 15.98M 1.09B 16.24M 113M 44.95M 570M 42.89M 41.98M 1.8B
Net income -48.11M -43.09M -39.76M -35.98M -67.27M -4.58B -68.36M -474M -189M -2.4B -181M -177M -7.59B -47.52M -42.56M -39.27M -35.54M -66.45M -4.53B -67.52M -468M -187M -2.37B -178M -175M -7.5B
Net Debt -55.34M -49.57M -45.73M -41.38M -77.38M -5.27B -78.63M -546M -218M -2.76B -208M -203M -8.74B -127M -114M -105M -94.99M -178M -12.1B -180M -1.25B -500M -6.33B -477M -467M -20.05B
Projected Income Statement - Annual - Kalaris Therapeutics, Inc.
Logo Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Employees
20
Date Price Change Volume
26-10-29 US$2.130 +5.97% 23,168
26-10-28 US$2.010 +8.06% 47,611
26-10-27 US$1.860 +3.33% 51,127
26-10-26 US$1.800 -3.74% 36,033
26-10-23 US$1.870 -6.03% 25,406
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Kalaris Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.130USD
Average target price
17.67USD
Spread / Average Target
+729.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kalaris Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. KLRS Stock